GeneHealth - Your precision medicine

Vibratory Urticaria

Disease Details

Family Health Simplified

Buy Membership

Description: Vibratory urticaria is a rare condition where the skin develops hives and itching in response to vibrations.
Type: Vibratory urticaria is an autosomal dominant condition.
Signs And Symptoms: Hives, or urticaria, is a form of skin rash with red, raised, itchy bumps. They may also burn or sting. Hives can appear anywhere on the surface of the skin. Whether the trigger is allergic or not, a complex release of inflammatory mediators, including histamine from cutaneous mast cells, results in fluid leakage from superficial blood vessels. Hives may be pinpoint in size or several inches in diameter, they can be individual or confluent, coalescing into larger forms.About 20% of people are affected. Cases of short duration occur equally in males and females, lasting a few days and without leaving any long-lasting skin changes. Cases of long duration are more common in females. Cases of short duration are more common among children while cases of long duration are more common among those who are middle aged. Fewer than 5% of cases last for more than six weeks. The condition frequently recurs. In half of cases of hives, the cause remains unknown.Angioedema is a related condition (also from allergic and nonallergic causes), though fluid leakage is from much deeper blood vessels in the subcutaneous or submucosal layers. Individual hives that are painful, last more than 24 hours, or leave a bruise as they heal are more likely to be a more serious condition called urticarial vasculitis. Hives caused by stroking the skin (often linear in appearance) are due to a benign condition called dermatographic urticaria.
Prognosis: In those with chronic urticaria, defined as either continuous or intermittent symptoms lasting longer than 6 weeks, 35% of people are symptom free 1 year after treatment, while 29% have a reduction in their symptoms. Those with a longer disease duration typically have a worse prognosis, with greater symptom severity. Chronic urticaria is often accompanied by an intense pruritus, and other symptoms associated with a reduced quality of life and a high burden of co-morbid psychiatric conditions such as anxiety and depression.
Onset: Vibratory urticaria is a rare condition that can present in childhood, adolescence, or early adulthood. Symptoms typically arise shortly after exposure to vibrations, such as from using power tools or riding in a vehicle.
Prevalence: There is limited information on the exact prevalence of vibratory urticaria. It is considered a rare form of physical urticaria and is characterized by the rapid development of itchy hives and swelling in response to vibrations.
Epidemiology: Chronic urticaria is usually seen in those older than 40 years, it is more common in women. The prevalence of chronic urticaria is 0.23% in the United States.
Intractability: Vibratory urticaria is generally not considered intractable. It can be managed with lifestyle modifications, avoidance of triggers, and medications such as antihistamines. However, the response to treatment can vary among individuals.
Disease Severity: Vibratory urticaria is generally considered a mild condition. The severity of symptoms can vary among individuals, with most cases involving transient redness, swelling, and itching at the site of vibration exposure. In some situations, symptoms can be more bothersome but are typically not life-threatening. Systemic symptoms like headaches or fatigue are rare but can occur.
Healthcare Professionals: Disease Ontology ID - DOID:1554
Pathophysiology: The skin lesions of urticarial disease are caused by an inflammatory reaction in the skin, causing leakage of capillaries in the dermis, and resulting in an edema which persists until the interstitial fluid is absorbed into the surrounding cells.Hives are caused by the release of histamine and other mediators of inflammation (cytokines) from cells in the skin. This process can be the result of an allergic or nonallergic reaction, differing in the eliciting mechanism of histamine release.
Carrier Status: Carrier status for vibratory urticaria refers to individuals who carry a genetic mutation associated with the condition but may not exhibit symptoms themselves. A specific gene mutation on the ADGRE2 gene has been linked to this disorder. Carriers can potentially pass the mutated gene to their offspring, leading to the manifestation of vibratory urticaria if inherited.
Mechanism: Vibratory urticaria is a rare form of physical urticaria triggered by vibrational stimuli.

**Mechanism:**
The condition is characterized by the rapid development of hives, itching, and sometimes swelling following exposure to vibration. The symptoms typically appear within a few minutes of exposure and resolve within an hour.

**Molecular Mechanisms:**
The molecular mechanisms underlying vibratory urticaria are not completely understood, but research has implicated several factors:

1. **Mast Cell Degranulation**: Upon vibrational stimulation, mast cells in the skin degranulate, releasing histamine and other inflammatory mediators. This leads to the characteristic symptoms of urticaria, such as hives and itching.

2. **Mutations in ADGRE2**: Recent studies have identified mutations in the ADGRE2 gene, which encodes a protein involved in cell signaling. This mutation can lead to increased sensitivity of mast cells to mechanical stimuli, promoting their activation and subsequent degranulation.

These molecular insights are crucial for understanding the pathophysiology of vibratory urticaria and potentially for developing targeted therapies.
Treatment: Treatment for vibratory urticaria typically involves the following approaches:

1. **Avoidance**: Prevent exposure to vibratory stimuli when possible.
2. **Antihistamines**: Non-sedating antihistamines can help manage symptoms by blocking histamine release.
3. **Physical Barriers**: Wearing padding or other protective clothing to reduce direct vibration exposure.
4. **Medications**: In some cases, additional medications such as leukotriene inhibitors may be prescribed.

Consult a healthcare provider for a personalized treatment plan.
Compassionate Use Treatment: Vibratory urticaria is a rare condition characterized by the development of hives and redness in response to vibration. Compassionate use treatments, off-label, and experimental treatments for this condition may include:

1. **Antihistamines**: While primarily used for common allergic reactions, antihistamines (e.g., cetirizine, fexofenadine) can be used off-label to manage symptoms of vibratory urticaria by blocking the action of histamine.

2. **Omalizumab**: An anti-IgE monoclonal antibody that is FDA-approved for chronic idiopathic urticaria. It's used experimentally for various types of urticaria, including vibratory urticaria, to reduce symptoms by targeting IgE-mediated pathways.

3. **Montelukast**: A leukotriene receptor antagonist typically used for asthma and allergic rhinitis, has been employed off-label to address urticaria symptoms by inhibiting leukotriene pathways.

4. **Immunosuppressants**: In severe cases, drugs like cyclosporine may be considered off-label to suppress the immune system and reduce urticaria symptoms.

The use of these treatments should be under the guidance of a healthcare professional due to the potential for side effects and the need for proper dosing and monitoring.
Lifestyle Recommendations: Lifestyle recommendations for managing vibratory urticaria include:

1. **Avoid Triggers**: Identify and avoid activities that trigger vibrations, such as using power tools, riding bicycles, or running.

2. **Protective Gear**: Wear protective clothing or padding to minimize direct vibrations to the skin.

3. **Antihistamines**: Regular use of non-sedating antihistamines can help control symptoms, as recommended by a healthcare provider.

4. **Stress Management**: Practice stress-relief techniques like yoga or meditation, as stress can exacerbate symptoms.

5. **Skin Care**: Maintain a gentle skin care regimen to prevent additional irritation.

6. **Consultation**: Regularly consult with a dermatologist or allergist to monitor the condition and adjust the treatment plan as needed.
Medication: Drugs that have caused allergic reactions evidenced as hives include codeine, sulphate of morphia, dextroamphetamine, aspirin, ibuprofen, penicillin, clotrimazole, trichazole, sulfonamides, anticonvulsants, cefaclor, piracetam, vaccines, and antidiabetic drugs. The antidiabetic sulphonylurea glimepiride, in particular, has been documented to induce allergic reactions manifesting as hives.
Repurposable Drugs: Vibratory urticaria is a rare condition where exposure to vibration triggers the development of hives. Regarding repurposable drugs, there are limited specific therapies approved, but the following drugs have shown some efficacy:

1. **Antihistamines**: These are commonly used to manage symptoms of urticaria. Non-sedating antihistamines like cetirizine, loratadine, or fexofenadine can be effective.

2. **Leukotriene receptor antagonists**: Drugs like montelukast can be used in combination with antihistamines to manage symptoms.

3. **Omalizumab**: This monoclonal antibody, typically used for chronic idiopathic urticaria, has shown promise in case reports for vibratory urticaria.

Please consult a healthcare provider for personalized treatment options.
Metabolites: Vibratory urticaria is a rare condition characterized by the development of hives and sometimes systemic symptoms upon exposure to vibration. The exact metabolic pathways involved in vibratory urticaria are not fully understood, but histamine release from mast cells in response to the mechanical stimulus is a key component. Specific metabolites directly attributed to vibratory urticaria have not been well-documented in scientific literature.
Nutraceuticals: There is limited evidence to support the use of specific nutraceuticals for vibratory urticaria. It is recommended to consult a healthcare professional for personalized advice and treatment options.
Peptides: Vibratory urticaria is a rare form of physical urticaria (hives) triggered by vibration. A genetic mutation in the ADGRE2 gene has been implicated in this condition. The mutation affects a receptor on mast cells, leading to their abnormal activation and release of histamine upon exposure to vibratory stimuli.

Regarding peptides, a specific peptide-based therapeutic approach for vibratory urticaria is not well-established. Most treatments focus on general management of symptoms using antihistamines to counteract histamine release.

Regarding "nan," if this refers to nanoparticles, there is no current evidence to suggest that nanoparticles are used in the treatment or management of vibratory urticaria. Research in nanoparticle-based treatments is ongoing across various fields, but their application in this specific condition has not been documented.